| Chinook Therapeutics is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing precision medicines for kidney diseases. Co.'s pipeline is focused on kidney diseases with clinical pathways. Co.'s lead clinical program is atrasentan, an endothelin A receptor antagonist. Co.'s second product candidate, BION-1301, is an anti-APRIL monoclonal antibody also in development for patients with IgA nephropathy. Co. developing CHK-336 for the treatment of primary hyperoxaluria as well as secondary hyperoxaluria and idiopathic kidney stone formation. Co. is also conducting research programs in several other rare, severe chronic kidney diseases. We show 9 historical shares outstanding datapoints in our coverage of KDNY's shares outstanding history.|
Understanding the changing numbers of KDNY shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like KDNY versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching KDNY by allowing them to research KDNY shares outstanding history
as well as any other stock in our coverage universe.